NASDAQ:PULM Pulmatrix Q1 2026 Earnings Report $1.72 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.72 0.00 (0.00%) As of 07/2/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pulmatrix EPS ResultsActual EPS-$0.32Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APulmatrix Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APulmatrix Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time7:00AM ETUpcoming EarningsPulmatrix's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Pulmatrix Earnings HeadlinesPulmatrix Stock Short Interest Report | NASDAQ:PULM | BenzingaJuly 1, 2026 | benzinga.comPulmatrix (NASDAQ:PULM) Shares Pass Above 50-Day Moving Average - What's Next?June 27, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 5 at 1:00 AM | InvestorPlace (Ad)Pulmatrix Inc.: Pulmatrix Announces First Quarter 2026 Financial ResultsMay 15, 2026 | finanznachrichten.dePulmatrix Inc : PULMMay 15, 2026 | 247wallst.comPulmatrix Announces First Quarter 2026 Financial ResultsMay 15, 2026 | prnewswire.comSee More Pulmatrix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email. Email Address About PulmatrixPulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches. Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA). Another key candidate, PLX100, is being investigated for pulmonary sarcoidosis, a chronic inflammatory disease of the lungs. Both programs have progressed through preclinical and early clinical stages, demonstrating favorable tolerability profiles and the potential to reduce systemic side effects. Founded in 2005 and headquartered in Lexington, Massachusetts, Pulmatrix combines formulation science with pulmonary pharmacology to advance its pipeline. The company collaborates with leading academic institutions and clinical research centers across the United States to conduct studies in diverse patient populations, leveraging its R&D infrastructure to support efficient development pathways. Pulmatrix’s leadership team brings extensive experience in respiratory drug development and regulatory strategy. Focused on advancing its inhaled therapies through pivotal trials and strategic partnerships, the company aims to expand its portfolio into additional acute and chronic respiratory conditions, ultimately improving patient outcomes and quality of life.View Pulmatrix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off? Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
